A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders

Abstract

Purpose: An open-label, multicenter, phase II study was conducted to define the safety and antitumor activity of the monoclonal antibody SGN-30 in patients with CD30 +

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*

“…38,46 Monoclonal antibodies SGN-30, a chimeric monoclonal antibody to CD30, has been used in 13 patients with PCALCL. 40,47,48 In an open-label multicenter phase 2 study, 6 of 11 (55%) patients achieved CR and 3 of 11 (27%) patients showed partial remission (PR). 48 No disease progression was observed.…”

“…40,47,48 In an open-label multicenter phase 2 study, 6 of 11 (55%) patients achieved CR and 3 of 11 (27%) patients showed partial remission (PR). 48 No disease progression was observed. The treatment was well tolerated.…”

Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools

“…In a phase 2 study in which the same antibody was tested in CD30-positive, heavily pretreated patients with cutaneous ALCL, lymphomatoid papulosis, and transformed mycosis fungoides, SGN-30 showed clinical activity (complete or partial response) in 16 out of 23 patients. Specifically, in cutaneous ALCL, clinical activity was seen in all patients, with responses in 82% of the treated patients (47). These are encouraging results, especially given the mild side-effects profile.…”

Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome

“…198,199 In a phase II multicenter trial of patients with one or more primary cutaneous CD30ϩ lymphoproliferative disorder [primary cutaneous ALCL (PC-ALCL), lymphomatoid papulosis, or CD30ϩ MF], clinical responses were seen in 87% of patients with ALCL, CD30ϩ-transformed MF, and lymphomatoid papulosis. 198 Based on this study and high response rates seen in systemic relapsed ALCL, 2 investigator-initiated phase II trials of the tubulin inhibitor-conjugated MMAE to CD30 antibody brentuximab vedotin were conducted in patients with CD30ϩ CTCL. Patients in both studies received 1.8 mg/kg every 3 weeks up to 16 doses with global response as the primary end-point.…”